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The mortality rate of alveolar hemorrhage (AH) after allogeneic hematopoietic stem cell transplantation is
greater than 60% with supportive care and high-dose steroid therapy. We performed a retrospective cohort
analysis to assess the beneﬁts and risks of recombinant human factor VIIa (rFVIIa) as a therapeutic adjunct for
AH. Between 2005 and 2012, 57 episodes of AH occurred in 37 patients. Fourteen episodes (in 14 patients)
were treated with steroids alone, and 43 episodes (in 23 patients) were treated with steroids and rFVIIa. The
median steroid dose was 1.9 mg/kg/d (interquartile range [IQR], 0.8 to 3.5 mg/kg/d; methylprednisolone
equivalents) and did not differ statistically between the 2 groups. The median rFVIIa dose was 41 mg/kg (IQR,
39 to 62 mg/kg), and a median of 3 doses (IQR, 2 to 17) was administered per episode. Concurrent infection
was diagnosed in 65% of the episodes. Patients had moderately severe hypoxia (median PaO2/FiO2, 193 [IQR,
141 to 262]); 72% required mechanical ventilation, and 42% survived to extubation. The addition of rFVIIa did
not alter time to resolution of AH (P ¼ .50), duration of mechanical ventilation (P ¼ .89), duration of oxygen
supplementation (P ¼ .55), or hospital mortality (P ¼ .27). Four possible thrombotic events (9% of 43 episodes)
occurred with rFVIIa. rFVIIa in combination with corticosteroids did not confer clear clinical advantages
compared with corticosteroids alone. In patients with AH following hematopoietic stem cell transplantation,
clinical factors (ie, worsening infection, multiple organ failure, or recrudescence of primary disease) may be
more important than the beneﬁt of enhanced hemostasis from rFVIIa.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.dgments on page 977.
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14.03.015INTRODUCTION
Alveolar hemorrhage (AH) is a life-threatening compli-
cation of allogeneic hematopoietic stem cell transplantation
(HSCT) that occurs in 2% to 14% of recipients [1]. AH may
account for up to one-third of cases of acute respiratory
failure requiring mechanical ventilation after HSCT and has a
mortality rate of >60% [2-7]. Factors contributing to the
development of AH include graft-versus-host disease
(GVHD) and pulmonary endothelial and epithelial cell injurySociety for Blood and Marrow Transplantation.
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irradiation [8-10]. In addition to supportive care (eg, blood
product administration, oxygen therapy, mechanical venti-
lation), high-dose corticosteroids have been routinely used
to treat AH after HSCT [11-13].
Recent studies have noted similarities in the clinical
presentation, management, and high mortality of AH after
HSCT in the presence and absence of infection (infection-
associated AH [IAH] and diffuse alveolar hemorrhage [DAH],
respectively) [5,6]. The difﬁculty in clinically distinguishing
DAH from IAH raises the concern that high-dose corticoste-
roids may increase the risk of infection and cause harm.
Three agents have been used as adjunctive therapies to
enhance pulmonary hemostasis and to decrease the dose
and duration of corticosteroid therapy: aminocaproic acid
[14], tranexamic acid [15], and recombinant human factor
VIIa (rFVIIa). Aminocaproic acid and tranexamic acid both
inhibit plasmin, thereby impeding ﬁbrinolysis. rFVIIa pro-
motes hemostasis via both a tissue factor-dependent
pathway at sites of endothelial injury and a tissue fac-
toreindependent mechanism, directly activating factors IX
and X on the surface of activated platelets [16,17]. Although
rFVIIa was originally approved in the United States for use in
patients with hemophilia and inhibitors to factors VIII or IX
[18], off-label indications account for the vast majority of its
use [19-25]. Safety concerns regarding the risk of venous and
arterial thromboembolic events and an apparent lack of
clinical efﬁcacy in patients without hemophilia have been
noted [26-30].
Limited data are available regarding the off-label use of
rFVIIa in HSCT recipients [31]. A phase II study evaluating
rFVIIa for the treatment of hemorrhage after HSCT (including
7 patients with AH) did not demonstrate any overall bene-
ﬁcial effects [32]. Case reports of i.v. and i.p. rFVIIa have
suggested clinical improvement in HSCT recipients with AH
(Table S1); however, in a large case series of AH after HSCT
(reported as an abstract), rFVIIa did not improve outcomes
from respiratory failure or overall survival [33]. Thus, the
utility of adjunctive rFVIIa therapy for AH post-HSCT remains
uncertain.
Here we report the use of rFVIIa therapy for AH in a large
cohort of HSCT recipients. We evaluated the clinical factors
associated with rFVIIa administration, including dose,
timing, outcome, and thromboembolic events. The charac-
teristics and outcomes were compared in a cohort of rFVIIa
recipients and a contemporaneous cohort of patients with
AH treated with corticosteroids alone.
METHODS
An expanded Methods section is available in the online supplement.
Patient Identiﬁcation
Our hospital’s Institutional Review Board approved this study (11-CC-
N228) and granted awaiver of informed consent for its conduct. Three of our
hospital databases were queried to identify patients who developed AH
following HSCT performed between August 2004 and November 2012.
Diagnosis of AH
For this study, AH was deﬁned as the acute onset of signs and/or
symptoms of respiratory compromise with evidence of a new or worsening
diffuse alveolar pattern on chest radiography or computed tomography (CT)
scan. The diagnosis was established by either increasingly bloody return
during bronchoalveolar lavage and/or the presence of >20% hemosiderin-
laden macrophages, or clinical evidence of respiratory compromise with
new or worsening pulmonary inﬁltrates and hemoptysis (n¼ 2), blood from
an artiﬁcial airway (n ¼ 5), or histological evidence of AH at autopsy (n ¼ 1).
Three patients had experienced at least 1 episode of AH documented by
bronchoscopy within the previous 14 days. Alternative diagnoses, such asﬂuid overload or congestive heart failure, were excluded. The onset of AH
was determined retrospectively based on a thorough review of the medical
record and was deﬁned as the earliest date when either evidence of respi-
ratory compromise was noted or new widespread alveolar inﬁltrates were
detected. A recurrent episode of AH was deﬁned as new or worsening
hypoxemia requiring increasing supplemental oxygen or the need for me-
chanical ventilation, evidence of new or worsening alveolar inﬁltrates on
chest radiography, and clinical deterioration resulting in directed therapy
for AH (ie, starting or increasing corticosteroids and/or resuming rFVIIa
treatment). Patients meeting criteria for AH were classiﬁed as having either
DAH or IAH based on either the absence or presence of a concomitant lower
respiratory tract or bloodstream infection, respectively.
Patient Characteristics
Patient demographic data evaluated included underlying disease, pre-
morbid conditions, and transplantation-speciﬁc factors, including condi-
tioning regimens and GVHD prophylaxis. Laboratory and microbiological
data and clinical outcomes, including organ failures during AH episodes,
were reviewed.
CT Analysis
Chest CT scans completed 24 hours before or within 72 hours from the
onset of AHwere analyzedwith computer-aided diagnosis (CAD) techniques
to determine the extent and severity of hemorrhage in each patient group.
Quantitative metrics of the abnormal lung imaging patterns, including the
volume of pathological lung regions and the ratio of pathological lung vol-
ume to total lung volume, were analyzed.
Therapy for AH
Conventional therapy was deﬁned as corticosteroids and supportive
care (eg, supplemental oxygen and ventilatory support, transfusion of blood
products, antimicrobial therapy). Corticosteroid and/or rFVIIa dose and
duration of therapy were at the discretion of the treating physicians. Pa-
tients received platelet transfusions in an attempt to achieve a level
>50,000/mL, fresh-frozen plasma to normalize prothrombin time and acti-
vated partial thromboplastin time, and cryoprecipitate to achieve a ﬁbrin-
ogen level >100 mg/dL. The use of any other prohemostatic therapy before
or during an episode of AH was recorded.
To examine the effect of rFVIIa on episodes of AH, we compared 4
separate outcomes with patients treated with corticosteroids alone: (1)
intensive care unit (ICU) length of stay in all patients admitted speciﬁcally
for respiratory failure due to AH (rFVIIa, 23 patients; conventional therapy, 8
patients), (2) duration of mechanical ventilation for respiratory failure due
to AH (rFVIIa, 25 episodes; conventional therapy, 7 episodes), (3) time to
clinical resolution of AH (rFVIIa, 30 episodes; conventional therapy, 10 epi-
sodes), and (4) duration of supplemental oxygen use from onset of the initial
episode of AH (all initial episodes included from each group). For the ﬁrst 3
comparisons, the onset of the AH episode was deﬁned as either the date of
intubation in patients who required mechanical ventilation for AH or the
date of admission to the ICU for AH in those who did not require mechanical
ventilation. The resolution of an AH episode was deﬁned as either successful
extubation or discharge from the ICU for patients not requiring mechanical
ventilation. In some patients, duration of bleeding could not be accurately
ascertaineddfor example, a patient intubated for a reason other than AH
who then developed AH while receiving mechanical ventilation. In patients
who were transferred to the ICU and intubated for AH, time to extubation
served as an indication of bleeding resolution. Duration of supplemental
oxygen use was deﬁned as the time from the onset of the initial AH episode
to 24 hours after cessation of oxygen or death.
For each episode of AH, the total dose, daily mean dose, and maximum
daily dose (converted to methylprednisolone equivalents per kilogram)
were recorded. In 41 of 57 episodes, the duration of steroid therapy per AH
episode was calculated as the time from the onset of AH to either resolution
(ie, date of extubation or discharge from the ICU, as deﬁned above) or death.
In the 16 remaining episodes, the duration was determined based on a re-
view of the patient’s medical record. In patients treated with rFVIIa, the total
daily dose per kilogram, the number of doses administered per day during
an episode, the number of total doses given per episode and the mean daily
dose per kilogram (ie, total dose divided by the number of administrations
per day). Adverse events related to rFVIIa therapy were reviewed, and all
thrombotic complications occurring within 7 days of rFVIIa administration
were recorded.
Statistical Analysis
Categorical patient characteristics were compared using either Pear-
son’s chi-square test or Fisher’s exact test, as appropriate. Continuous pa-
tient characteristics were compared between 2 groups using Welch’s t test.
Episode-level variables were compared using linear mixed models with
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Standard residual diagnostics were used to check model assumptions. Log-
transformation was applied when necessary. The log-rank test was used to
compare survival times from the date of transplantation and the onset of AH
in the 2 treatment groups. Survival times from the onset of AH were also
compared in the 2 treatment groups between patients with DAH and those
with IAH. Propensity scores (generated using logistic regression) were used
to adjust for key baseline differences between the 2 groups by stratiﬁcation
and regression adjustment. Analyses were conducted using either R version
2.15.1 (http://www.R-project.org) or SAS version 9.4 (SAS Institute, Cary,
NC). All P values are 2-tailed and are considered signiﬁcant at P  .05.RESULTS
Patient Characteristics
Between 2005 and 2012, 648 patients underwent allo-
geneic HSCT at the National Institute’s of Health Clinical
Center, of whom 37 (5.7%) developed AH. Baseline patient
and transplantation characteristics were similar in the rFVIIa
and conventional treatment groups (Table 1). Twenty-nine of
these 37 patients (78%) underwent HSCT after a reduced-
intensity conditioning regimen, and 33 patients (89%)
received a peripheral blood stem cell transplant (Table 1).
Time to engraftment, absolute lymphocyte count at day 30,
and incidence of cytomegalovirus reactivation were similar
in the 2 groups, as was the incidence of acute and chronic
GVHD before the diagnosis of AH.AH
Fifty-seven episodes of AH occurred in the 37 patients.
Fourteen episodes of AH occurring in 14 patients were
treated with conventional therapy. The remaining 43 epi-
sodes, occurring in 23 patients, were treated with rFVIIa in
addition to conventional therapy. Episodes occurred as early
as 5 days post-HSCT and as late as almost 7 years post-HSCT
(Figure S1). AHwas conﬁrmed by bronchoscopy in 86% of the
episodes (35 in the rFVIIa group and all 14 in the conven-
tional therapy group). Fifty-six episodes were treated in the
ICU (98%). Ten of the 23 patients (10 of 23) in the rFVIIa group
experienced 2 or more discrete AH episodes, separated by a
median of 17 days (interquartile range [IQR], 11 to 41 days)
(Table 2 and Figure S1). None of the patients treated with
conventional therapy alone developed recurrent AH.
GVHD prophylaxis given at the onset of each AH episode
was similar in the 2 groups, as was the addition of adjunctive
immunosuppression at any time during an AH episode
(Table 2 and Table S2) and the degree of thrombocytopenia
during the ﬁrst 3 days of an episode (Table 2 and Figure S2).
Prolonged prothrombin time and activated partial throm-
boplastin time at the onset of AH was seen in both groups.
The majority of the patients in both groups had moderately
severe hypoxemia, with amedian PaO2/FiO2 ratio of 193 (IQR,
141 to 262), and more than two-thirds required mechanical
ventilatory support (Table 2) [34].
Hospital mortality, as well as 30-, 60-, and 180-day sur-
vival rates, did not differ signiﬁcantly between the 2 groups
(Table 2). Median overall survival after the onset of the initial
AH episode was 80 days in the conventional therapy group
and 49 days in the rFVIIa group (P ¼ .97) (Figure 1; Figure S3
presents long-term survival curves). To adjust for important
baseline differences between the 2 groups, we generated
propensity scores using the following variables from the ﬁrst
episode of AH: maximum Sequential Organ Failure Assess-
ment (SOFA) score [35], need for vasopressor support, need
for renal replacement therapy, lower respiratory tract
infection, and bloodstream infection. Despite adjustment
based on the propensity score using either stratiﬁcation(P ¼ .24) or regression (P ¼ .79) there was no difference in
hospital mortality between the 2 treatment groups.
Twenty-seven of the 37 patients with AH underwent at
least 1 CT scan during the study period (40 total scans). The
median ratio of pathological lung parenchyma (consolidation
and ground-glass opacities) at the onset of AH was similar in
the 2 groups (16.4% [IQR, 12.7% to 28.9%] in the conventional
therapy group and 23.8% [IQR, 17.9% to 32.5%] in the rFVIIa
group; P ¼ .37) (Figure S4). Results were similar when
accounting for pleural ﬂuid volume (data not shown).
Representative images showing increasing amounts of
parenchymal involvement are shown in Figure 2A-E. Images
demonstrating the distinction between parenchymal in-
ﬁltrates and pleural effusion and showing changes in
parenchymal and pleural abnormalities over time in patients
with recurrent AH episodes are presented in Figure S5 and
Video S3. In patients who experienced multiple AH episodes,
parenchymal inﬁltrates recurred in a similar radiographic
distribution as seen in their initial episode (Video S3).
Treatment of AH
Corticosteroid therapy was administered in 95% of the AH
episodes overall (14 of 14 episodes in the conventional
therapy group and 40 of 43 episodes in the rFVIIa group;
Table 3). The corticosteroid dose was not increased above the
pre-AH dose in 29% of the episodes (4 of 14) in the conven-
tional therapy group (median pre-AH methylprednisolone
dose, 70 mg/d) and in 14% of the episodes (6 of 43) in the
rFVIIa group (median pre-AH methylprednisolone dose,
55 mg/d). In 3 episodes occurring in 2 patients in the rFVIIa
group, corticosteroids were not given. The total dose, daily
mean dose, and highest daily dose was similar in the 2
groups (Table 3).
All patients who received rFVIIa during their initial AH
episode were treated with rFVIIa during each subsequent
episode. The ﬁrst rFVIIa dose was given within the ﬁrst
48 hours after the onset of AH in 70% of the episodes (30 of
43), and 53% of the episodes (23 of 43) were treated on day 0,
suggesting that the majority of patients were treated early
rather than as a rescue therapy. The median rFVIIa dose was
41 mg/kg (IQR, 39 to 62 mg/kg), and patients received a me-
dian of 3 doses (IQR, 2 to 17 doses) (Table 3). The mean daily
dose of rFVIIa per patient decreased over time (P ¼ .007;
Figure S6A) and the total daily dose of rFVIIa paralleled this
decrease (P ¼ .08; Figure S6B). ICU length of stay, duration of
mechanical ventilation, time to resolution of bleeding, and
duration of oxygen supplementation were similar in the 2
treatment groups (Figure 3).
Incidence and Types of Infection Concurrent with AH
DAH occurred in 5 of 14 episodes treated with conven-
tional therapy and in 15 of 43 episodes treated with rFVIIa. In
the rFVIIa group, 3 patients accounted for 12 of the 15 epi-
sodes of DAH. IAH was present in 64% of the episodes (9 of
14) treated with conventional therapy and in 65% of the
episodes (28 of 43) treated with rFVIIa (Figure S1). A lower
respiratory tract infectionwas detected in 47% of the total AH
episodes (27 of 57; conventional therapy group, 6 episodes in
6 patients; rFVIIa group, 21 episodes in 15 patients)
(Table S3). Ten episodes of IAH were associated with
concomitant bacteremia (conventional group, 3 episodes in 3
patients; rFVIIa group, 5 episodes in 4 patients) or fungemia
(rFVIIa group, 2 episodes in 1 patient) in the absence of a
lower respiratory tract infection (Table S4). Survival from the
onset of the ﬁrst AH episode was similar in the 2 treatment
Table 1
Baseline Patient and Transplantation Characteristics
Characteristic rFVIIa (n ¼ 23) Conventional Therapy (n ¼ 14) P Value
Sex, males/females, n 13/10 8/6 1.00
Age, median (range) 36 (9-66) 45 (13-59) .32
Primary disease, n .08
Acute lymphoblastic leukemia 1 3
Acute myelogenous leukemia 3 3
Chronic lymphocytic leukemia 2 1
Hodgkin disease 1 1
Myelodysplastic syndrome 1 1
Non-Hodgkin lymphoma 4 5
Severe aplastic anemia 6 0
Other* 5 0
Pulmonary function, median (IQR)y
FVC, L 3.30 (2.59-3.96) 3.72 (2.57-3.90) .44
FVC, % predicted 90 (78-103) 82 (73-103) .53
FEV1, L 2.60 (1.92-3.05) 3.02 (2.18-3.17) .79
FEV1, % predicted 95 (74-104) 87 (72-98) .39
Diffusion capacity, % predicted 62 (55-78) 68 (66-78) .29
Comorbidities, n (%) .71z
Coronary artery disease 1 (4) 1 (7)
Cerebrovascular disease 2 (9) 2 (14)
Venous thromboembolism 3 (13) 3 (21)
Conditioning regimens
Reduced-intensity conditioning, n (%) 19 (83) 10 (71) .44
Fludarabine/cyclophosphamide 8 (35) 7 (50)
Fludarabine/cyclophosphamide and equine antithymocyte globulin 7 (30) 0
Other 4 (18)x 3 (21)x
Total body irradiation, n (%) 9 (39) 6 (43) 1.00
Myeloablative regimenk 3 (13) 4 (29)
Reduced-intensity regimen{ 6 (26) 2 (14)
Stem cell source, n (%) .14
Peripheral blood only 20 (87) 13 (93)
Bone marrow 0 1 (7)
Peripheral and cord blood 3 (13) 0
Matched transplants, n (%) .69
Related 11 (65) 10 (77)
Unrelated 6 (35) 3 (23)
Mismatched transplants, n (%) 1.00
Related 2 (33) 1 (100)
Unrelated 1 (17) 0
Related and unrelated 3 (50)# 0
Post-transplantation course, n (%)
Time to engraftment, d, median (IQR) 15 (12-17)** 12 (10-15) .50
Absolute lymphocyte count at day þ30, cells /mL, median (IQR) 452 (206-789)yy 520 (200-1107)zz .94
Cytomegalovirus reactivation, n (%)xx 14 (61) 5 (36) .37
Incidence of acute GVHD before AH, n (%) 11 (48) 8 (57) .83
Incidence of chronic GVHD before AH, n (%) 8 (35) 4 (29) 1.00
Donor lymphocyte infusion, n (%)kk 6 (26) 4 (29) .83
Stem cell boost, n (%)kk 5 (22) 4 (29) .70
FVC indicates forced vital capacity; FEV1, forced expiratory volume in 1 second.
* Other includes multiple myeloma, sickle cell disease, chronic granulomatous disease, GATA2 deﬁciency, and thalassemia.
y All pulmonary function testing was done before transplantation except in 4 patients (3 in the rFVIIa group and 1 in the conventional group) in whom testing
was done post-transplantation but before any episodes of AH. Pulmonary function testing data were not available for 2 patients in the conventional group.
z Comparison of the number of patients in each group with at least 1 comorbidity.
x rFVIIa group: alemtuzumab, n ¼ 2; alemtuzumab and busulfan, n ¼ 1; EPOCH-FR, n ¼ 1; conventional therapy group: EPOCH-F, n ¼ 2; pentostatin, n ¼ 1.
k In 6 of 7 patients, total body irradiation was given twice daily for 4 days as part of a myeloablative conditioning regimen. The total dose was 1200 cGy (eight
150-cGy fractions) with a 600-cGy mediastinal boost (eight 75-cGy fractions). One patient in the rFVIIa group received 400 cGy (eight 50-cGy fractions) of total
body irradiation as part of a myeloablative regimen.
{ The dose of total body irradiation therapy given as part of reduced-intensity conditioning regimens ranged from 200 cGy to 400 cGy.
# Three patients received a haploidentical (related mismatched) and cord blood (unrelated mismatched) transplant.
** Three patients failed to engraft.
yy Two patients had a total leukocyte count of <50, and 1 patient died before day þ30.
zz One patient died before day þ30.
xx Cytomegalovirus reactivation requiring antiviral therapy before or within 7 days after an initial episode of AH.
kk Number of patients who received 1 or more donor lymphocyte infusions or stem cell boosts 60 days before the initial episode of AH.
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with IAH (P ¼ .56; Figure 4B).
Incidence of Thrombotic Events in Patients Treated
with rFVIIa
Thrombotic complications possibly related to rFVIIa
therapy were noted in 9% (4 of 43) of AH episodes, occurringbetween less than 1 hour and up to 4 days after rFVIIa
administration. These included a blood clot obstructing an
endotracheal tube, a basilic vein thrombosis associated with
a peripherally inserted central catheter, and 2 cases of
disseminated intravascular coagulation (DIC) before death, 1
resulting in the loss of pulses in 2 extremities (occurring
2 days after rFVIIa administration) and the other associated
Table 2
Episodes of AH
Characteristic rFVIIa
(43 Episodes in 23 Patients)
Conventional Therapy
(14 Episodes in 14 Patients)
P Value
Timing of AH post-transplantation, d, median (IQR) 156 (72-514) 86 (17-183) .52
Patients with 2 episodes, n (%) 10 (43) 0 (0) .006
Episodes per patient, n, median (IQR) 1 (1-2) 1 (1-1) .014
Interval between episodes, d, median (IQR) 17 (11-41) d d
GVHD prophylaxis, n (%)
Cyclosporine 17 (40) 5 (36) 1.00
Tacrolimus 8 (19) 3 (21) 1.00
Sirolimus 10 (23) 5 (36) .49
Mycophenolate mofetil 3 (7) 3 (21) .15
More than 1 agent 4 (9) 4 (29) .09
None 9 (21) 2 (14)* .71
Laboratory variables at onset of AH, median (IQR)
Platelet count, 103/mL 43,000 (23,000-61,000) 33,500 (25,000-63,000) .60
Prothrombin time, sy 15.1 (14.0-17.0)z 16.5 (14.9-18.3) .58
Activated partial thromboplastin time, sy 39.1 (32.3-44.9)z 40.4 (35.1-43.2) .85
ANC, cells/mL 1712 (838-4422)x 3720 (1024-4852)k .39
ALC, cells/mL 268 (95-944)x,{ 255 (115-642)k .42
Organ failures
SOFA score, median (IQR)# 13 (11-18) 12 (11-14) .23
Need for MV, n (%) 32 (74) 9 (64) .64
Highest PaO2/FiO2 at the onset of AH, median (IQR)** 188 (143-243) 260 (134-347) .30
Vasopressor use, n (%) 6 (14) 0 (0) .32
Need for renal replacement therapy, n (%) 12 (28) 2 (14) .48
Outcomes
Hospital mortality in patients requiring MV for AH, n (%) 13/21 (62) 6/9 (67) 1.00
Overall hospital mortality, n (%) 15 (65) 6 (43) .27
30-day survival rate, n (%) 14 (61) 11 (79) .31
60-day survival rate, n (%) 11 (48) 6 (43) 1.00
180-day survival rate, n (%) 8 (35) 4 (29) 1.00
ANC indicates absolute neutrophil count; ALC, absolute lymphocyte count; MV, mechanical ventilation; PaO2, arterial oxygen tension; FiO2, fraction of inspired
oxygen.
* Two patients were treated with daclizumab and inﬂiximab alone at the onset of AH.
y Prothrombin time: normal range, 11.8-14.7 s; activated partial thromboplastin time: normal range, 23.4-34.5 s.
z Data not available for 2 episodes.
x Four patients had a total leukocyte count <30.
k Two patients had a total leukocyte count <150.
{ One patient with chronic lymphoblastic leukemia not included.
# PaO2 values were not available for calculating the respiratory variable in 10 episodes (rFVIIa group, n ¼ 7; conventional therapy group, n ¼ 3). In 3 episodes
occurring in the rFVIIa-treated group, the variable could be imputed based on oxygen saturation values. The remaining 7 episodes were excluded in the main
comparison (P ¼ .23). In a secondary analysis, missing respiratory values were imputed using the lowest possible value in the rFVIIa group and the highest
possible value in the conventional group to recalculate the median SOFA score: median, 12 (IQR, 9-16) and 11 (IQR, 9-14), respectively (P ¼ .19).
** Highest PaO2/FiO2 within the ﬁrst 24 hours of AH onset. A minority of patients in both groups did not undergo blood gas analysis within the ﬁrst 24 hours of
AH onset (rFVIIa group: 5 patients, 8 episodes; conventional group: 3 patients, 3 episodes).
Figure 1. Survival in the rFVIIa and conventional therapy groups. Shown are
Kaplan-Meier survival curves depicting outcomes in the ﬁrst 180 days after
onset of the initial AH episode. The solid line represents the rFVIIa group; the
dashed line, the conventional therapy group.
J.M. Elinoff et al. / Biol Blood Marrow Transplant 20 (2014) 969e978 973with hemolysis and severe metabolic acidosis (occurring
12 hours after rFVIIa administration).
Causes of Death
In the conventional therapy group, 57% of the patients (8
of 14) survived to hospital discharge. One death was related
to AH and respiratory failure due an angioinvasive mold
infection. Three patients died due to progression of their
underlying disease, 1 patient died of respiratory failure due
to pneumonia, and 1 patient died of sepsis and multiorgan
failure.
In the rFVIIa group, 35% of the patients (8 of 23) survived to
hospital discharge. Four patients died from respiratory failure
due to AH; 3 of these patients had a concurrent infection (1
each with Acinetobacter baumannii pneumonia, parainﬂuenza
pneumonia, and Pseudomonas aeruginosa bacteremia). One
death in the rFVIIa group was attributed to progression of
underlyingmalignancy. The remaining deathswere attributed
to multiorgan failure in the setting of disseminated fungal
infection (n¼ 4), DIC (n¼ 2), carbapenem-resistant Klebsiella
pneumoniae infection (n¼ 2), and multiple infections (n¼ 2).
Figure 2. Extent of radiographic pulmonary pathology at the onset of AH. Shown are representative surface renderings of pulmonary parenchymal pathology at the
onset of AH from 5 different patients in the rFVIIa group. (A) Patient 8; 8%. (B) Patient 21; 20%. (C) Patient 5; 25%. (D) Patient 13; 37%. (E) Patient 11; 47%. Total lung
volume is outlined in blue, and pathological areas are highlighted in light green.
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talization. This patient was rehospitalized 3 years later and
ultimately died of multiorgan failure in the setting of para-
inﬂuenza pneumonia and AH.Postmortem Analysis of Lung Parenchyma
Autopsies were performed in 36% of the patients (5 of 14)
in the conventional therapy group and in 30% of those (7 of
23) in the rFVIIa group. Histopathological ﬁndings included
intra-alveolar hemorrhage with hemosiderin-laden macro-
phages with elements of diffuse alveolar damage, including
type II pneumocyte hyperplasia, focal hyaline membranes,
and ﬁbrin accumulation. In addition, 8 autopsies demon-
strated evidence of organizing pneumonia with inﬂamma-
tion (Table 4 and Figure 5A-D). C4d-positive staining was
noted mainly in larger vessels and within ﬁbrinous depositsTable 3
Treatment of AH
Therapy rFVIIa
(n ¼ 43 Episodes in 23
Corticosteroids, median (IQR)*
Total dose per episode, mg/kg 14.6 (4.8-37.6)
Daily mean dose per episode, mg/kg/d 1.8 (0.8-3.6)
Highest daily dose per episode, mg/kg/d 2.8 (1.2-7.9)
rFVIIa
Dose per administration, mg/kg, median (IQR) 41 (39-62)
Doses per episode, n, median (IQR) (range) 3 (2-17) (1-
Cumulative dose per episode, mg, median (IQR) 16 (4.8-37.6)
Additional hemostatic agents used, n (%)
Desmopressin acetate 8 (18.6)
Aminocaproic acid 2 (4.7)
Conjugated estrogens 1 (2.3)
* Expressed in methylprednisolone equivalents.and hyaline membranes, but was usually negative in small-
caliber vessels and capillaries (Figure 5C and D).DISCUSSION
In this retrospective cohort study, we assessed the ben-
eﬁts and risks of the off-label use of rFVIIa in patients with
AH following HSCT. AH was associated with substantial use
of blood products, pharmaceuticals, and intensive care re-
sources. More than one-third of the patients had AH without
evidence of lower respiratory tract or bloodstream infection,
whereas the remaining patients had a concomitant infection
associated with AH. The majority of AH episodes were
associated with acute respiratory distress syndrome, re-
quiring mechanical ventilatory support. The lung injury was
characterized by intra-alveolar hemorrhage with diffuse
alveolar damage and organizing pneumonia owing in part toPatients)
Conventional Therapy
(n ¼ 14 Episodes in 14 Patients)
P Value
12.6 (5.0-31.9) .42
2.1 (1.4-2.5) .68
2.2 (2.0-9.6) .97
d
57) d
d
.43
1 (7.1)
1 (7.1)
0
Figure 3. Effect of rFVIIa therapy on ICU length of stay (LOS), duration of
mechanical ventilation (MV), resolution of AH, and duration of supplemental
oxygen use in the rFVIIa and conventional therapy groups. There was no
between-group difference in ICU length of stay due to AH (episodes included
in analysis: rFVIIa, 23 of 43; conventional therapy, 8 of 14; P ¼ .63), duration of
mechanical ventilation due to AH (rFVIIa, 25 of 43; conventional therapy, 7 of
14; P ¼ .89), time to resolution of AH (rFVIIa, 30 of 43; conventional therapy, 10
of 14; P ¼ .50), or duration of supplemental oxygen use from the onset of the
initial episode of AH (rFVIIa, 23 of 23; conventional therapy, 14 of 14; P ¼ .55).
Figure 4. Survival in patients with DAH and IAH. Shown are Kaplan-Meier
survival curves depicting outcomes in the ﬁrst 180 days after onset of the
initial episode of AH in patients with DAH (A) and patients with IAH (B). The
solid line represents the rFVIIa group; the dashed line, the conventional
therapy group.
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and indirect effects of infection [36,37]. As such, anti-
inﬂammatory and antimicrobial therapies were the corner-
stones of therapy.
Our ﬁndings indicate that rFVIIa can be a useful adjuvant
therapy along with corticosteroids and supportive care in the
treatment of AH. However, the resulting enhanced coagula-
tion from rFVIIa administration does not confer a survival
advantage compared with corticosteroid therapy alone.
Other factors, such as worsening infection, multiorgan fail-
ure, or recrudescence of primary disease, may outweigh any
survival beneﬁt of enhanced hemostasis in HSCT recipients
with AH.
Previous reports suggest better outcomes associated with
AH episodes occurring during the periengraftment period
and within the ﬁrst 30 days after HSCT compared with epi-
sodes occuring at later time points post-transplant [3,5]. The
AH episodes in our series occurred later after HSCT than
those in previous reports, and 27% of our patients experi-
enced 2 or more episodes of AH. The 30-, 60- and 180-day
survival rates were comparable to or better than the rates
previously reported for patients with AH occurring within
the ﬁrst 30 days post-transplantation [4-6,38]. Improve-
ments in supportive care may have contributed to some of
these differences in outcomes. In addition, previous
chemotherapy and radiation exposure, presence of GVHD,
and concurrent infections contributed to patient heteroge-
neity and likely affected the effectiveness of the new therapy
in these patients.
In early studies, the most frequent causes of death in
HSCT recipients with AH were sepsis and multiorgan failure
[1,4,12], whereas refractory hypoxemic respiratory failure
has been reported inmore recent studies [3,6]. Studies on the
contribution of infection to outcome after AH have yielded
conﬂicting results [5,6]. In the present study, death due to
refractory hypoxemia and respiratory failure was uncom-
mon, and most of the patients had active infection detected
in proximity to an episode of AH. Compared with previous
studies [5,6,38], our cohort had a higher incidence of lower
respiratory tract and bloodstream infections with gram-
negative bacilli, molds, and fungi. These infections might
have contributed directly to pulmonary endothelial and
epithelial injury or indirectly by promoting a proin-
ﬂammatory state and the development of GVHD [39].
Furthermore, the preponderance of infection-related deaths
in this patient population underscores the difﬁculty of
accurately determining the efﬁcacy of adjunctive rFVIIa for
AH, because any potential beneﬁt from enhanced hemostasis
is unlikely to affect outcome in patients who ultimately die of
sepsis and multiorgan system failure.
Recurrent AH episodes occurred in almost one-half of the
patients treated with rFVIIa, but in none of the patients
receiving conventional therapy alone. Recurrent AH alone
may reﬂect a more severely immunocompromised patient
population. In this setting, rFVIIa might have had a tempo-
rizing effect on the clinical course pending the effects of
more deﬁnitive anti-inﬂammatory and antimicrobial ther-
apy. The high rate of recurrence noted only in the patients
treated with rFVIIa may suggest a detrimental effect of rFVIIa
in the setting of AH. Hyaline membrane formation was more
common in postmortem histopathology in the rFVIIa group,
possibly reﬂecting more severe lung injury or a consequence
of the earlier timing of autopsy after AH. rFVIIa administra-
tion in healthy adults modestly increases plasma IL-6 and
IL-8 levels, an effect that may be potentiated in critically ill
Table 4
Postmortem Histopathology after AH
rFVIIa (n ¼ 7) Conventional Therapy (n ¼ 5)
Time of autopsy relative to last dose of therapy for AH, d, median (IQR) 3 (2-3) 20 (7-26)
Death due to respiratory failure, n (%) 2 (29) 1 (20)
Histopathological ﬁndings, n
Dilated airspaces with intra-alveolar hemorrhage in different stages of
organization with partial clot formation and ﬁbrin accumulation
7 5
Type II pneumocyte hyperplasia 7 5
Hemosiderin laden-macrophages (alveoli and interstitium)* 6 5
Focal hyaline membranes lining alveolar spaces 6 1
Organizing pneumonia with inﬂammation 5 3
Angioinvasive fungal infection 2 1
Underlying hematologic malignancy 1y 2z
Thromboemboli 0 0
* One patient without hemosiderin laden macrophages died 1 day after recurrence of AH.
y Gray zone lymphoma.
z Epstein-Barr viruseassociated lymphoproliferative disorder and nodular sclerosing Hodgkin lymphoma.
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cytokine production is likely multifactorial, related to
thrombin generation [40,41], activated factor X production
[42], or a direct effect of rFVIIa [43]. The relevance of these
mechanisms to the inﬂammatory state that exists after HSCT
is unknown; however, in a recent meta-analysis of its off-
label use for intracranial hemorrhage, cardiac surgery, body
trauma, brain trauma, and liver transplantation, rFVIIa ther-
apy was not associated with increased mortality in any of
these groups [29]. In contrast, rFVIIa therapy was associated
with a decreased risk of acute respiratory distress syndrome
in body trauma [29].
Recent systematic reviews and meta-analyses have
highlighted the increased risk of arterial thromboembolic
events with rFVIIa use in patients without hemophilia
[27-30]. The relative risk of arterial thrombotic complications
was associatedwith advanced age at cardiac surgery [28] andFigure 5. Autopsy sections of representative lung histopathology. (A) Hematoxyli
hemosiderin-laden macrophages in alveolar spaces. (Original magniﬁcation, 20.) (B)
and interstitial spaces. (Original magniﬁcation, 20.) (C and D) C4d staining highl
(Original magniﬁcation, 20.)with rFVIIa doses >40 mg/kg in patients with intracranial
hemorrhage [29], conditions that typically affect an elderly
patient population. In contrast, no increased risk of arterial
thromboembolic events was detected in a younger cohort of
patients with body trauma [29]. HSCT recipients represented
aminority of the patients included in these studies, however,
and thus the applicability of these ﬁndings to these patients
is uncertain. The dearth of adverse events data from ran-
domized, controlled trials of rFVIIa use in HSCT recipients
and/or patients with hematologic malignancies underscores
the fact that risk factors for thrombotic events in this pop-
ulation are unknown and may differ signiﬁcantly from those
in patients included in larger systematic reviews and meta-
analyses [28,31,44]. In the only randomized, placebo-
controlled trial of rFVIIa for bleeding after HSCT reported to
date, the median patient age was 37 years, and there was no
evidence of increased thromboembolic events with rFVIIan and eosin staining showing accumulation of red blood cells, ﬁbrin, and
Iron staining highlighting hemosiderin-laden macrophages within the alveolar
ighting predominantly large-caliber vessels (C) and hyaline membranes (D).
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rent use of prophylactic doses of heparin in 22% of patients
may have mitigated the risk of thromboembolism in that
study [32,45]. Similarly, a retrospective study reported no
thrombotic complications in 24 patients treated with rFVIIa
for AH post-HSCT [33]. Here we report 4 thrombotic events
possibly related to rFVIIa, including a blood clot obstructing
an endotracheal tube, an adverse event that has been re-
ported previously [46]. All 4 of our patients were dependent
on platelet transfusions at the time of rFVIIa administration,
indicating that thrombocytopenia is not protective against
thrombosis or DIC. We cannot suggest any screening tool to
identify those patients whomight develop thrombosis or DIC
with the use of rFVIIa in this setting.
The minimum effective dose of rFVIIa for severe bleeding
in patients without hemophilia is unknown. Doses used in
clinical trials have varied greatly, from as low as 5 mg/kg up to
200 mg/kg given either as a single dose ormultiple doses with
varying frequencies [30]. Decisions regarding dose are
particularly relevant to the risk of arterial thrombotic com-
plications that appear to be dose-dependent [28]. In patients
with intact mechanisms of thrombin generation, higher
rFVIIa doses may augment thrombin production distant to
the site of bleeding in a tissue factoreindependent manner,
producing thromboembolic complications without im-
proved hemostatic effects [47]. In vitro data suggest that a
low dose of rFVIIa (equivalent to 20 mg/kg) has similar efﬁ-
cacy as higher doses (100 to 200 mg/kg) as measured by
thrombin generation [48]. Similarly, in moderate to severe
thrombocytopenia, 50 mg/kg of rFVIIa was as effective as
100 mg/kg in decreasing the Ivy bleeding time [49].
Compared with previous reports of rFVIIa therapy for AH
after HSCT (Table S1), in our cohort the median dose per
kilogram was lower and decreased over time, suggesting
increased experience with this therapy with similar clinical
effects.
Strengths of this study include the detailed data collec-
tion and analysis of each AH episode, an assessment of
concurrent infections, long-term follow up of each patient,
and inclusion of a contemporaneous comparator cohort
treated with corticosteroids and supportive care alone.
Nonetheless, several selection biases for and against the use
of rFVIIa likely contributed to our inability to demonstrate
any clear advantage or disadvantage of rFVIIa therapy for AH
in this cohort. As a single-site retrospective study, selection
and ascertainment bias, as well as unknown confounders,
might have inﬂuenced our observations. In addition, our
analysis is likely underpowered to assess some of the clinical
variables (ie mortality, duration of mechanical ventilation,
ICU length of stay, and resolution of AH) compared in the 2
treatment groups.
In conclusion, rFVIIa used in combination with cortico-
steroids did not confer a survival advantage compared with
corticosteroids alone. Any putative advantage as adjunctive
therapy with corticosteroids and supportive care will require
a prospective randomized clinical trial. Further insight into
the pathogenic mechanisms contributing to lung injury in
individual patients with AH likely will inform therapeutic
options and possibly provide the basis for improved
therapies.
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